| In the News | |||
News about Perlegen from external sources. Perlegen's Chief Scientific Officer David Cox, M.D., Ph.D, joins David Lester, New York Site Head of Global Clinical Technology at Pfizer Global Research & Development, and other thought leaders in the Drug Discovery space, to discuss the importance of the role of Biomarkers in the Drug Development Industry. [Podcast] (Requires free registration.) [August 2007] Pfizer Buying Into Perlegen’s Pharmacogenomics Platform [PDF] Mayo, Perlegen Release Whole-Genome SNP Map of Parkinson's [PDF] Perlegen's Phyllis Whiteley on the New PGx Flavor of Drug-Licensing
Deals [PDF] Perlegen Sciences' Recipe for Success [PDF] Perlegen SNP Bonanza Spurs HapMap Project [PDF] ‘Matchmaker’ SNP Study Paves Way For Pharmacogenomics [PDF] Landmarks of Human Variations [PDF] Consensus Emerges on HapMap Strategy [PDF] Human
Genetics: Perfect match Pharmacogenomics checklist [PDF] Perlegen Signs AstraZeneca, Plus Two Deals With Pfizer [PDF] All-Stars
Profile: David Cox, Superior in SNPs/Genotyping David
Cox: Finding Genetic Hot Spots Using Genome-wide Scans You
Can't Make a Monkey Out of Us Taking
Data Storage to Infinity — and Beyond Analyzing
the Genome Biotech
claims comprehensive SNP map Perlegen
moves into a new phase-and new headquarters 3
start-ups make all the right moves Chips
show DNA differences Perlegen
completes $100 million financing DNA
test compares 50 people |
|||